ProQR Therapeutics (PRQR) Non-Current Debt (2021 - 2023)

ProQR Therapeutics (PRQR) has disclosed Non-Current Debt for 3 consecutive years, with $4.6 million as the latest value for Q4 2023.

  • Quarterly Non-Current Debt rose 5.98% to $4.6 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Dec 2023, up 5.98% year-over-year, with the annual reading at $4.6 million for FY2023, 6.55% up from the prior year.
  • Non-Current Debt hit $4.6 million in Q4 2023 for ProQR Therapeutics, up from $4.4 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $45.0 million in Q4 2021 to a low of $4.4 million in Q4 2022.
  • Historically, Non-Current Debt has averaged $18.0 million across 3 years, with a median of $4.6 million in 2023.
  • Biggest five-year swings in Non-Current Debt: tumbled 90.31% in 2022 and later increased 5.98% in 2023.
  • Year by year, Non-Current Debt stood at $45.0 million in 2021, then crashed by 90.31% to $4.4 million in 2022, then rose by 5.98% to $4.6 million in 2023.
  • Business Quant data shows Non-Current Debt for PRQR at $4.6 million in Q4 2023, $4.4 million in Q4 2022, and $45.0 million in Q4 2021.